Glycation of apolipoprotein C1 impairs its CETP inhibitory property: Pathophysiological relevance in patients with type 1 and type 2 diabetes

Diabetes Care

Volumn 37, Issue 4, 2014, Pages 1148-1156

  Bouillet, Benjamin ^a,b   Gautier, Thomas ^b   Blache, Denis ^b   Pais De Barros, Jean Paul ^b   Duvillard, Laurence ^b   Petit, Jean Michel ^a,b   Lagrost, Laurent ^b   Vergès, Bruno ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C1; CHOLESTEROL ESTER TRANSFER PROTEIN; HEMOGLOBIN A1C; METHYLGLYOXAL; TRIACYLGLYCEROL; GLUCOSE;

ADULT; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; ISOELECTRIC POINT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; STATIC ELECTRICITY; TRIACYLGLYCEROL BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; FEMALE; MALE; METABOLISM; MIDDLE AGED;

ADULT; APOLIPOPROTEIN C-I; CHOLESTEROL ESTER TRANSFER PROTEINS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HUMANS; MALE; MIDDLE AGED;

EID: 84897891836     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1467     Document Type: Article

References (39)

1. Malmendier CL, Lontie JF, Grutman GA, Delcroix C. Metabolism of apolipoprotein C-I in normolipoproteinemic human subjects. Atherosclerosis 1986;62:167-172 (Pubitemid 16004148)
2. Westerterp M, de Haan W, Berbée JFP, Havekes LM, Rensen PCN. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res 2006;47:1203-1211 (Pubitemid 43830712)
3. Havel RJ, Fielding CJ, Olivecrona T, Shore VG, Fielding PE, Egelrud T. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. Biochemistry 1973;12:1828-1833
4. Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J Lipid Res 2002;43:2136-2145 (Pubitemid 35471082)
5. Berbée JFP, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PCN. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 2005;46:297-306 (Pubitemid 40271094)
6. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem 1990;265:22453-22459 (Pubitemid 120014322)
7. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 1991;266:18259-18267 (Pubitemid 21908074)
8. Shachter NS, Ebara T, Ramakrishnan R, et al. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J Clin Invest 1996;98:846-855 (Pubitemid 26349190)
9. Jong MC, Dahlmans VE, van Gorp PJ, et al. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest 1996;98:2259-2267 (Pubitemid 26394199)
10. Jong MC, Gijbels MJ, Dahlmans VE, et al. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest 1998;101:145-152 (Pubitemid 28058913)
11. Jong MC, van Dijk KW, Dahlmans VE, et al. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem J 1999;338:281 -287
12. Gautier T, Masson D, de Barros JP, et al. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem 2000;275:37504 -37509
13. Gautier T, Masson D, Jong MC, et al. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice. J Biol Chem 2002;277:31354-31363 (Pubitemid 34968934)
14. Gautier T, Masson D, Jong MC, et al. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice. Biochem J 2005;385:189-195
15. Dumont L, Gautier T, de Barros J-PP, et al. Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI. J Biol Chem 2005;280:38108-38116 (Pubitemid 41642426)
16. de Barros J-PP, Boualam A, Gautier T, et al. Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma. J Lipid Res 2009;50:1842-1851
17. Pillois X, Gautier T, Bouillet B, et al. Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease. J Lipid Res 2012;53:1200-1209
18. Berbée JFP, Mooijaart SP, de Craen AJM, et al. Plasma apolipoprotein CI protects against mortality from infection in old age. J Gerontol A Biol Sci Med Sci 2008;63:122-126 (Pubitemid 351738440)
19. Schmitt A, Schmitt J, Münch G, Gasic-Milencovic J. Characterization of advanced glycation end products for biochemical studies: side chain modifications and fluorescence characteristics. Anal Biochem 2005;338:201-215 (Pubitemid 40312584)
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
21. Dautin G, Soltani Z, Ducloux D, et al. Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase. Kidney Int 2007;72:871-878 (Pubitemid 47462079)
22. Zeller M, Masson D, Farnier M, et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 2007;50:1948-1955 (Pubitemid 350046332)
23. Guyard-Dangremont V, Lagrost L, Gambert P, Lallemant C. Competitive enzyme-linked immunosorbent assay of the human cholesteryl ester transfer protein (CETP). Clin Chim Acta 1994;231:147-160 (Pubitemid 24376923)
24. Tournier JF, Bayard F, Tauber JP. Rapid purification and activity of apolipoprotein C1 on the proliferation of bovine vascular endothelial cells in vitro. Biochim Biophys Acta 1984;804:216-220 (Pubitemid 14122609)
25. Sparks DL, Phillips MC. Quantitative measurement of lipoprotein surface charge by agarose gel electrophoresis. J Lipid Res 1992;33:123-130
26. de Vries R, Perton FG, Dallinga-Thie GM, et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005;54:3554-3559 (Pubitemid 43334349)
27. Masson D, Athias A, Lagrost L. Evidence for electronegativity of plasma high density lipoprotein-3 as one major determinant of human cholesteryl ester transfer protein activity. J Lipid Res 1996;37:1579-1590 (Pubitemid 26249987)
28. Sammett D, Tall AR. Mechanisms of enhancement of cholesteryl ester transfer protein activity by lipolysis. J Biol Chem 1985;260:6687-6697 (Pubitemid 15005855)
29. Desrumaux C, Athias A, Masson D, Gambert P, Lallemant C, Lagrost L. Influence of the electrostatic charge of lipoprotein particles on the activity of the human plasma phospholipid transfer protein. J Lipid Res 1998;39:131-142 (Pubitemid 28063549)
30. Colhoun HM, Scheek LM, Rubens MB, et al. Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 2001;50:652-659 (Pubitemid 32195232)
31. Riemens S, van Tol A, Sluiter W, Dullaart R. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998;140:71-79 (Pubitemid 28378456)
32. Dullaart RP. Plasma lipoprotein abnormalities in type 1 (insulin-dependent) diabetes mellitus. Neth J Med 1995;46:44-54
33. Eckel RH, Albers JJ, Cheung MC, Wahl PW, Lindgren FT, Bierman EL. High density lipoprotein composition in insulindependent diabetes mellitus. Diabetes 1981;30:132-138 (Pubitemid 11018681)
34. Kahri J, Groop PH, Viberti G, Elliott T, Taskinen MR. Regulation of apolipoprotein A-I-containing lipoproteins in IDDM. Diabetes 1993;42:1281-1288 (Pubitemid 23259847)
35. Winocour PH, Durrington PN, Ishola M, Anderson DC. Lipoprotein abnormalities in insulin-dependent diabetes mellitus. Lancet 1986;1:1176-1178 (Pubitemid 16122423)
36. Cohn JS, Tremblay M, Batal R, et al. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 2002;43:1680-1687 (Pubitemid 35168282)
37. Guerin M, Le Goff W, Duchene E, et al. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol 2008;28:148-154
38. Hooper AJ, Burnett JR. Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opin Investig Drugs 2012;21:1427-1432
39. Villard EF, El Khoury P, Duchene E, et al. Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women. Arterioscler Thromb Vasc Biol 2012;32:2341-2349